Last reviewed · How we verify
HFA MDI
HFA MDI is a hydrofluoroalkane-based metered-dose inhaler formulation that delivers aerosolized medication directly to the respiratory tract.
At a glance
| Generic name | HFA MDI |
|---|---|
| Also known as | Propellant in MDI |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
HFA MDI refers to a drug delivery system rather than a specific active pharmaceutical ingredient. HFA (hydrofluoroalkane) propellants replaced chlorofluorocarbon (CFC) propellants in metered-dose inhalers due to environmental concerns. The MDI (metered-dose inhaler) mechanism uses pressurized gas to aerosolize and deliver a precise dose of medication to the lungs for local or systemic absorption.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (PHASE4)
- Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants (PHASE3)
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (PHASE3)
- Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma (PHASE3)
- A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype (EARLY_PHASE1)
- Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |